Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Travere Therapeutics Inc (TVTX)

Travere Therapeutics Inc (TVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,527,584
  • Shares Outstanding, K 89,472
  • Annual Sales, $ 233,180 K
  • Annual Income, $ -321,550 K
  • EBIT $ -91 M
  • EBITDA $ -50 M
  • 60-Month Beta 0.85
  • Price/Sales 5.67
  • Price/Cash Flow N/A
  • Price/Book 33.98

Options Overview Details

View History
  • Implied Volatility 62.18% (+8.69%)
  • Historical Volatility 73.03%
  • IV Percentile 41%
  • IV Rank 13.61%
  • IV High 170.07% on 01/12/26
  • IV Low 45.18% on 09/19/25
  • Expected Move (DTE 29) 3.77 (12.69%)
  • Put/Call Vol Ratio 2.98
  • Today's Volume 3,734
  • Volume Avg (30-Day) 8,405
  • Put/Call OI Ratio 1.19
  • Today's Open Interest 53,143
  • Open Int (30-Day) 73,809
  • Expected Range 25.96 to 33.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.00
  • Number of Estimates 7
  • High Estimate 0.46
  • Low Estimate -0.31
  • Prior Year -0.73
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.59 +31.61%
on 01/13/26
42.13 -29.43%
on 12/24/25
-6.77 (-18.55%)
since 12/22/25
3-Month
22.59 +31.61%
on 01/13/26
42.13 -29.43%
on 12/24/25
+2.25 (+8.19%)
since 10/22/25
52-Week
12.91 +130.29%
on 04/09/25
42.13 -29.43%
on 12/24/25
+10.27 (+52.77%)
since 01/22/25

Most Recent Stories

More News
TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm

The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). ...

TVTX : 29.73 (+5.24%)
Stocks Fall on Weakness in Software and Credit Card Companies

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.19%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.80%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.18%. March E-mini...

GOOGL : 330.54 (+0.66%)
INTU : 547.69 (+4.34%)
JPM : 303.63 (+0.53%)
$IUXX : 25,518.35 (+0.76%)
ZNH26 : 111-200 (+0.03%)
MSFT : 451.14 (+1.58%)
ESH26 : 6,944.75 (unch)
MA : 532.86 (+1.00%)
V : 326.36 (+0.33%)
AMD : 253.73 (+1.57%)
$DOWI : 49,384.01 (+0.63%)
CMG : 40.54 (-0.44%)
Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS

New PDUFA target action date is April 13, 2026 Commercial launch preparations continue in anticipation of potential approval

TVTX : 29.73 (+5.24%)
Stock Indexes Slip as the Magnificent Seven Technology Stocks Retreat

The S&P 500 Index ($SPX ) (SPY ) is down -0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.55%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.26%. March E-mini S&P futures (ESH26...

GOOGL : 330.54 (+0.66%)
AAPL : 248.35 (+0.28%)
B : 49.24 (+0.35%)
HL : 31.29 (+8.34%)
CDE : 25.77 (+12.48%)
JPM : 303.63 (+0.53%)
$IUXX : 25,518.35 (+0.76%)
ZNH26 : 111-200 (+0.03%)
MSFT : 451.14 (+1.58%)
TSLA : 449.36 (+4.15%)
ESH26 : 6,944.75 (unch)
MA : 532.86 (+1.00%)
Stocks Little Changed Despite a Fed-Friendly US Core CPI Report

The S&P 500 Index ($SPX ) (SPY ) is down -0.02%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.36%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.09%. March E-mini S&P futures (ESH26...

B : 49.24 (+0.35%)
HL : 31.29 (+8.34%)
CDE : 25.77 (+12.48%)
JPM : 303.63 (+0.53%)
$IUXX : 25,518.35 (+0.76%)
ZNH26 : 111-200 (+0.03%)
ESH26 : 6,944.75 (unch)
MA : 532.86 (+1.00%)
V : 326.36 (+0.33%)
IBP : 304.45 (-0.58%)
AMD : 253.73 (+1.57%)
$DOWI : 49,384.01 (+0.63%)
Travere Therapeutics Provides Corporate Update and 2026 Outlook

U.S. FILSPARI reaches all-time highs of 908 new PSFs and net product sales of approximately $103 million in 4Q 2025 Company positioned for successful commercial launch...

TVTX : 29.73 (+5.24%)
Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 44 th Annual J.P. Morgan Healthcare Conference...

TVTX : 29.73 (+5.24%)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on December 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to five new employees, consisting...

TVTX : 29.73 (+5.24%)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on November 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, consisting...

TVTX : 29.73 (+5.24%)
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025

New late-breaking data from DUPLEX Study show significantly more FILSPARI ® (sparsentan)-treated patients achieved proteinuria below 0.7 g/g compared with irbesartan ...

TVTX : 29.73 (+5.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 32.10
2nd Resistance Point 30.94
1st Resistance Point 30.33
Last Price 29.73
1st Support Level 28.56
2nd Support Level 27.40
3rd Support Level 26.79

See More

52-Week High 42.13
Fibonacci 61.8% 30.97
Last Price 29.73
Fibonacci 50% 27.52
Fibonacci 38.2% 24.07
52-Week Low 12.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar